Ratings Lytix Biopharma

Equities

LYTIX

NO0010405780

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-06-25 EDT			5-day change	1st Jan Change
9.3 ^NOK	-6.06%		+2.88%	+91.36%

05-30	Transcript : Lytix Biopharma AS, Q1 2024 Earnings Call, May 30, 2024
05-30	Lytix Biopharma AS Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
Based on current prices, the company has particularly high valuation levels.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
LYTIX BIOPHARMA	+91.36%	43.49M	-
MODERNA, INC.	+38.36%	52.73B	B-
LONZA GROUP AG	+36.73%	39B	A
IQVIA HOLDINGS INC.	-8.63%	38.52B	B
ALNYLAM PHARMACEUTICALS, INC.	+25.46%	30.38B	B
CELLTRION, INC.	-11.17%	26.39B	C
ICON PUBLIC LIMITED COMPANY	+11.44%	26.08B	B-
UNITED THERAPEUTICS CORPORATION	+45.09%	14.15B	B+
MEDPACE HOLDINGS, INC.	+32.93%	12.6B	C+
BIO-TECHNE CORPORATION	-5.30%	11.51B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes